1816-91-7

Usage

Uses

Used in Coordination Chemistry:
1-(2-amino-2-oxoethyl)triaza-1,2-dien-2-ium is used as a ligand for [forming complexes with transition metals] for [catalytic reactions]. Its triaza-1,2-diene structure and positively charged nitrogen atom allow it to effectively complex with transition metals, enhancing the efficiency of various catalytic processes.
Used in Medicinal Chemistry:
1-(2-amino-2-oxoethyl)triaza-1,2-dien-2-ium is used as a building block for [developing new drugs and pharmaceuticals] for [its potential applications in medicinal chemistry]. 1-(2-amino-2-oxoethyl)triaza-1,2-dien-2-ium's unique structure and properties make it a promising candidate for the design and synthesis of novel therapeutic agents.
Used in Chemical and Biological Processes:
1-(2-amino-2-oxoethyl)triaza-1,2-dien-2-ium is used as a versatile ligand for [various chemical and biological processes] for [its ability to participate in a wide range of reactions and interactions]. 1-(2-amino-2-oxoethyl)triaza-1,2-dien-2-ium's structural features and positive charge enable it to play a crucial role in diverse applications, contributing to the advancement of chemical and biological research.

Upstream product

• 637-81-0 ethyl-2-azidoacetate 
• 79-07-2 Chloroacetamide 
• 683-57-8 bromo-acetic acid amide 
• 1668-10-6 glycinamide hydrochloride 

Downstream Products

• 13838-08-9 Azidamfenicol 
• 598-41-4 H-Gly-NH₂ 
• 73565-25-0 1-cyclohexyl-5-cyclohexylaminotetrazole 
• 1184933-26-3 C₂₀H₂₈N₆O₃ 
• 2620-63-5 2-acetamidoacetamide 
• 1333427-86-3 C₁₆H₂₁N₅O₂S 
• 1542517-86-1 C₂₁H₁₉N₅O₃ 
• 1542518-65-9 C₁₀H₁₀N₄O 
• 1542517-76-9 C₂₃H₁₆N₄O 
• 1542517-79-2 C₁₇H₁₂N₄O 
• 1542517-82-7 4-methyl-3-(4-phenyl-1H-1,2,3-triazol-1-yl)quinolin-2(1H)-one 
• 1542518-54-6 1-phenyldibenzo[c,f][1,2,3]triazolo[1,5-a][1,7]naphthyridin-5(6H)-one 
• 1542518-13-7 C₁₆H₁₇N₅O 
• 1542518-15-9 C₁₇H₁₃N₅O₂ 

Relevant academic research and scientific papers

A study of the thermal decomposition of 2-azidoacetamide by ultraviolet photoelectron spectroscopy and matrix-isolation infrared spectroscopy: Identification of the imine intermediate H2NCOCHNH

The thermal decomposition of 2-azidoacetamide (N3CH 2CONH2) has been studied by matrix-isolation infrared spectroscopy and real-time ultraviolet photoelectron spectroscopy. N 2, CH2NH, HNCO, CO, NH3, and HCN are observed as high-temperature decomposition products, while at lower temperatures, the novel imine intermediate H2NCOCH=NH is observed in the matrix-isolation IR experiments. The identity of this intermediate is confirmed both by ab initio molecular orbital calculations of its IR spectrum and by the temperature dependence and distribution of products in the photoelectron spectroscopy (PES) and IR studies. Mechanisms are proposed for the formation and decomposition of the intermediate consistent both with the observed results and with estimated activation energies based on pathway calculations.

COMPOUNDS FOR THE MODULATION OF CYCLOPHILINS FUNCTION

The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof useful as inhibitors of Cyclophilins and modulators of cyclophilin-like proteins. The invention also relates to uses of said compounds in the treatment of various disorders. Formula (I), wherein: R1 and R2 are each independently is selected from the group consisting of -R, -haloalkyl, -hydroxyalkyl, -OR, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, and - N(R)2; wherein R2 could also be a sulphide; each R is independently hydrogen, C 1-6 aliphatic, C3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, sulphur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms selected from nitrogen, oxygen, or sulphur; R3 is Formual (Ia) selected from the group consisting of -OEt, and wherein R5 and R6 are independently selected from the group consisting of H, halide, methoxy, thiomethyl, morpholine and trifluoromethyl;R4 is selected from the group consisting of C1-6-alkyl-, and R4.1-CH2- wherein, R4.1 is C3-6-cycloalkyl-, a 5-6 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, sulphur; optionally substituted with one R4.1.1 wherein, R4.1.1 is selected from -H, C1-4-alkyl, optionally substituted with one substituent selected from H2N(O)C- or EtO(O)C-;X is carbon or nitrogen; A is selected from the group consisting of 6 membered unsaturated ring, with 1-3 nitrogen atoms, which is optionally substituted by -NH2,and Formula (Ib), wherein ring B is a fused 5-10 membered saturated or partially unsaturated heterocyclic mono- bicyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen or sulphur, which is optionally substituted by -OH; and m is 1 or 2; and n is 1 or 2.

Synthesis of (1H-1,2,3-Triazol-1-yl)acetic Acid Derivatives

Abstract: A convenient synthetic approach to (1H-1,2,3-triazol-1-yl)acetic acid derivatives via the reaction of azidoacetamides with β-ketoesters and acetylacetone is proposed. Based on this strategy, 1,5-disubstituted 1,2,3-triazoles were prepared from available reagents under metal-free conditions. A one-pot protocol for the synthesis of (5-methyl-1H-1,2,3-triazol-1-yl)acetamides derived from N-substituted chloroacetamides is developed.

Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus

Inspired by our previous efforts on the modifications of diarylpyrimidines as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTI) and reported crystallography study, novel diarylnicotinamide derivatives were designed with a “triazole tail” occupying the entrance channel in the NNRTI binding pocket of the reverse transcriptase to afford additional interactions. The newly designed compounds were then synthesized and evaluated for their anti-HIV activities in MT-4 cells. All the compounds showed excellent to good activity against wild-type HIV-1 strain with EC50 of 0.02–1.77 μM. Evaluations of selected compounds against more drug-resistant strains showed these compounds had advantage of inhibiting E138K mutant virus which is a key drug-resistant mutant to the new generation of NNRTIs. Among this series, propionitrile (3b2, EC50(IIIB) = 0.020 μM, EC50(E138K) = 0.015 μM, CC50 = 40.15 μM), pyrrolidin-1-ylmethanone (3b8, EC50(IIIB) = 0.020 μM, EC50(E138K) = 0.014 μM, CC50 = 58.09 μM) and morpholinomethanone (3b9, EC50(IIIB) = 0.020 μM, EC50(E138K) = 0.027 μM, CC50 = 180.90 μM) derivatives are the three most promising compounds which are equally potent to the marketed drug Etravirine against E138K mutant strain but with much lower cytotoxicity. Furthermore, detailed SAR, inhibitory activity against RT and docking study of the representative compounds are also discussed.

Substituted diaryl nicotinamide type derivative, and preparation method and application thereof

The invention relates to a substituted diaryl nicotinamide type derivative, and a preparation method and application thereof, in particular to a substituted diaryl nicotinamide type derivative shown as the general formula I and pharmaceutically-acceptable salt thereof. The invention further provides a preparation method of the compound of the general formula I, and application of a composition, comprising one or more compounds, in preparation of drugs for treating and preventing human immunodeficiency virus (HIV) infection.

6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS

The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

Synthesis and Evaluation of a Library of Trifunctional Scaffold-Derived Compounds as Modulators of the Insulin Receptor

We designed a combinatorial library of trifunctional scaffold-derived compounds, which were derivatized with 30 different in-house-made azides. The compounds were proposed to mimic insulin receptor (IR)-binding epitopes in the insulin molecule and bind to and activate this receptor. This work has enabled us to test our synthetic and biological methodology and to prove its robustness and reliability for the solid-phase synthesis and testing of combinatorial libraries of the trifunctional scaffold-derived compounds. Our effort resulted in the discovery of two compounds, which were able to weakly induce the autophosphorylation of IR and weakly bind to this receptor at a 0.1 mM concentration. Despite these modest biological results, which well document the well-known difficulty in modulating protein-protein interactions, this study represents a unique example of targeting the IR with a set of nonpeptide compounds that were specifically designed and synthesized for this purpose. We believe that this work can open new perspectives for the development of next-generation insulin mimetics based on the scaffold structure.

HETEROARYL NITRILE COMPOUNDS USEFUL AS INHIBITORS OF CATHEPSIN-S

Disclosed are Cathepsin-S reversible inhibitor compounds of the formula (I) which are useful in the treatment of autoimmune and other diseases. Also disclosed are pharmaceutical compositions containing the same, and methods of making and using the same.

Triazole substituted aminobenzophenone compounds

The invention relates to novel compounds according to formula Ia and Ib, said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases, or cancer.